Questcor's Sole Opportunity

In this video, Brenton Flynn describes Questcor Pharmaceuticals' primary opportunity.  It's a drug called Acthar, a long acting gel that slowly releases a natural hormone called ACTH.  Even though ACTH was approved 60 years ago, Questcor has seen sales of Acthar double this past year, with a projected earnings growth of 20% for the upcoming year. Selling at less than 7.5 times future earnings and paying a 3% dividend, Questcor looks like an attractive value stock.

Learn the full story
Questcor is one of the most debated names in all of biotech. Will insurance companies continue to cover Acthar? Will a government investigation lead to big fines? We highlight these high-profile issues inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.


Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 20, 2013, at 10:57 AM, NotTheDroid wrote:

    Oh thank goodness Brenton finally learned

    1) how to pronounce Acthar (not Actar like in most of his videos)

    2) that the ACTH in the name actually stands for the hormone. he was confused for quite a while on what the active ingredient was.

    What he is still suffering from is 'shortitis'. While he is slowly becoming educated, he still has a short bias.

    He doesn't know how many insurance companies have reconfirmed coverage in the last 2 months. Why? Because he doesn't do research. He parrots what shorts tell him to say.

    He doesn't know that there are multiple indications for Acthar that are entirely unrelated to each other. IS and MS prescriptions could stagnate as they build thier 'PIPELINE' for NS (already growing rapidly) and PM/DM which is expected to produce good results this quarter with a lot of growth for next.

    I could go on, but it's pointless. His analysis speaks for itself. He is short, doesn't do research, and parrots what shorts want him to say.

    Amazing that he has a title like Bureau Chief, aye?

  • Report this Comment On February 20, 2013, at 10:58 AM, NotTheDroid wrote:

    BTW Brenton, did you know that FSGS is an orphan disease and is being treated with Acthar?

  • Report this Comment On February 20, 2013, at 11:50 AM, drdonrs wrote:

    Brenton, you are probably a nice guy, but as an analyst you don't cut the mustard. You might just be qualified to do huckster type commercials on cable, you know the kind like Gold Bond's denture cream. Here masquerading as an expert on stocks and Questcor, in particular...well you leave a lot to be desired.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2265571, ~/Articles/ArticleHandler.aspx, 11/26/2014 9:06:02 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement